Exor Capital LLP acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating ) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 11,522,187 shares of the company’s stock, valued at approximately $92,984,000. Teva Pharmaceutical Industries makes up approximately 8.6% of Exor Capital LLP’s portfolio, making the stock its 6th largest holding. Exor Capital LLP owned approximately 1.04% of Teva Pharmaceutical Industries at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of TEVA. Private Trust Co. NA acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth about $32,000. Credit Agricole SA acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth about $34,000. Newbridge Financial Services Group Inc. grew its position in Teva Pharmaceutical Industries by 555.6% in the third quarter. Newbridge Financial Services Group Inc. now owns 5,900 shares of the company’s stock valued at $48,000 after purchasing an additional 5,000 shares during the last quarter. Ritholtz Wealth Management bought a new position in Teva Pharmaceutical Industries in the third quarter worth about $85,000. Finally, MQS Management LLC bought a new position in Teva Pharmaceutical Industries in the second quarter valued at about $89,000. The institutional investors and hedge funds own 50.39% of the company’s stock.
Price performance of Teva Pharmaceutical Industries
TEVA stock opened at $10.23 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94. Teva Pharmaceutical Industries Limited has a one year low of $6.78 and a one year high of $11.44. The firm has a market cap of $11.36 billion, a PE ratio of -8.85 and a beta of 1.20. The firm has a 50 day moving average of $9.48 and a 200 day moving average of $9.06.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating ) last posted its quarterly earnings data on Thursday, November 3rd. The company reported $0.56 EPS for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a negative net margin of 8.52% and a positive return on equity of 26.97%. The firm had revenue of $3.60 billion for the quarter, compared to analysts’ expectations of $3.86 billion. analysts forecast that Teva Pharmaceutical Industries Limited will post 2.4 earnings per share for the current year.
Wall Street analysts forecast growth
A number of brokerages recently issued reports on TEVA. Piper Sandler decreased their target price on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an “underperform” rating for the company in a research report on Wednesday, November 23rd. Jefferies Financial Group lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and upped their target price for the company from $10.00 to $12.00 in a research report on Thursday, January 19th. JPMorgan Chase & Co. downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and cut their target price for the company from $11.00 to $10.00 in a research report on Monday, November 14th. UBS Group lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a research report on Friday, November 4th. Finally, StockNews.com began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 12th. They assign a “buy” rating to the company. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average price target of $10.67, based on data from MarketBeat.
Profile of Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceutical products in North America, Europe and internationally. The company offers sterile products, hormones, high-potency drugs and cytotoxic agents in a variety of dosage forms, including tablets, capsules, injections, inhalants, liquids, transdermal patches, ointments and creams.
Want to see what other hedge funds hold TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE: TEVA – Get Rating).
This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Teva Pharmaceutical Industries, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients daily. MarketBeat identified the five stocks top analysts are quietly whispering to their clients to buy now before the broader market takes a nosedive … and Teva Pharmaceutical Industries wasn’t on the list.
While Teva Pharmaceutical Industries currently has a “Hold” rating among analysts, the top-rated analysts think these five stocks are better buys.
Check out the five stocks here